Juno Therapeutics Inc (JUNO) EVP Sells $355,631.35 in Stock

Juno Therapeutics Inc (NASDAQ:JUNO) EVP Robert Azelby sold 4,157 shares of Juno Therapeutics stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $85.55, for a total transaction of $355,631.35. Following the sale, the executive vice president now owns 89,614 shares in the company, valued at $7,666,477.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Robert Azelby also recently made the following trade(s):

  • On Thursday, February 8th, Robert Azelby sold 3,497 shares of Juno Therapeutics stock. The shares were sold at an average price of $85.77, for a total transaction of $299,937.69.
  • On Thursday, February 1st, Robert Azelby sold 4,167 shares of Juno Therapeutics stock. The shares were sold at an average price of $85.78, for a total transaction of $357,445.26.
  • On Monday, January 22nd, Robert Azelby sold 102,539 shares of Juno Therapeutics stock. The shares were sold at an average price of $86.25, for a total transaction of $8,843,988.75.
  • On Wednesday, January 17th, Robert Azelby sold 29,131 shares of Juno Therapeutics stock. The shares were sold at an average price of $68.61, for a total transaction of $1,998,677.91.
  • On Monday, December 18th, Robert Azelby sold 1,816 shares of Juno Therapeutics stock. The shares were sold at an average price of $44.96, for a total transaction of $81,647.36.

Juno Therapeutics Inc (NASDAQ:JUNO) opened at $85.10 on Friday. Juno Therapeutics Inc has a 1-year low of $19.62 and a 1-year high of $86.28. The stock has a market cap of $9,855.08, a PE ratio of -25.18 and a beta of 3.43. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.

Several hedge funds and other institutional investors have recently made changes to their positions in JUNO. Teachers Advisors LLC raised its stake in shares of Juno Therapeutics by 15.4% in the second quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock worth $2,219,000 after acquiring an additional 9,890 shares during the last quarter. BlackRock Inc. raised its stake in shares of Juno Therapeutics by 2.6% in the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after acquiring an additional 110,503 shares during the last quarter. New York State Common Retirement Fund raised its stake in shares of Juno Therapeutics by 8.7% in the second quarter. New York State Common Retirement Fund now owns 137,700 shares of the biopharmaceutical company’s stock worth $4,116,000 after acquiring an additional 10,999 shares during the last quarter. UBS Asset Management Americas Inc. raised its stake in shares of Juno Therapeutics by 78.7% in the second quarter. UBS Asset Management Americas Inc. now owns 53,439 shares of the biopharmaceutical company’s stock worth $1,597,000 after acquiring an additional 23,539 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Juno Therapeutics by 11.8% in the second quarter. Northern Trust Corp now owns 382,631 shares of the biopharmaceutical company’s stock worth $11,438,000 after acquiring an additional 40,468 shares during the last quarter. 68.90% of the stock is owned by institutional investors.

Several brokerages have recently weighed in on JUNO. Citigroup lowered shares of Juno Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 17th. Needham & Company LLC lowered shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. Maxim Group reiterated a “buy” rating and set a $56.00 target price on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Wells Fargo & Co downgraded shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 12th. Finally, Wedbush downgraded shares of Juno Therapeutics from an “outperform” rating to a “neutral” rating in a report on Wednesday, January 17th. Two research analysts have rated the stock with a sell rating, sixteen have given a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $51.20.

WARNING: This news story was published by BBNS and is the sole property of of BBNS. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/juno-therapeutics-inc-juno-evp-sells-355631-35-in-stock/1887960.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped


Leave a Reply

 
© 2006-2018 BBNS.